文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

DNA甲基化抑制剂改善Danon病X连锁相关自噬失败

Amelioration of X-Linked Related Autophagy Failure in Danon Disease With DNA Methylation Inhibitor.
PubMed 文献 · Circulation · 2016-09-27

本研究利用Danon病患者来源的诱导多能干细胞分化的心肌细胞(iPSC-CMs)建立疾病模型,发现X染色体随机失活导致女性患者表型差异,DNA去甲基化剂5-aza-2'-deoxycytidine可重新激活沉默的LAMP2等位基因并改善自噬失败,为个体化iPSC平台用于疾病建模和药物筛选提供依据。

要点

  • 女性Danon病表型差异源于X染色体随机失活
  • 患者iPSC-CMs重现Danon病组织学特征和自噬失败
  • 5-aza-2'-deoxycytidine可重新激活沉默LAMP2并改善自噬失败

核心结论

  • iPSC-CMs平台揭示X染色体随机失活对Danon病疾病表型的贡献,并证明DNA甲基化抑制剂可改善自噬失败。

研究设计与样本

  • 利用全外显子测序在一个Danon病家系中鉴定LAMP2基因无义突变(c.520C>T,外显子4)。
  • 从患病母亲及其2个儿子的体细胞生成iPSC系,并分化为心肌细胞(iPSC-CMs)进行疾病建模。

主要发现

  • 患者iPSC-CMs在体外重现Danon病的组织学特征和自噬失败。
  • X染色体上野生型和突变型LAMP2等位基因的随机失活是女性患者异常表型的原因。
  • 5-aza-2'-deoxycytidine在女性患者iPSC和iPSC-CMs中重新激活沉默的LAMP2等位基因并改善自噬失败。

临床怎么用

  • 患者特异性iPSC平台可用于Danon病的疾病建模和药物筛选。
  • DNA甲基化抑制剂可能作为女性Danon病的潜在治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Danon disease is an X-linked disorder that leads to fatal cardiomyopathy caused by a deficiency in lysosome-associated membrane protein-2 (LAMP2). In female patients, a later onset and less severe clinical phenotype have been attributed to the random inactivation of the X chromosome carrying the mutant diseased allele. We generated a patient-specific induced pluripotent stem cell (iPSCs)-based model of Danon disease to evaluate the therapeutic potential of Xi-chromosome reactivation using a DNA methylation inhibitor. METHODS: Using whole-exome sequencing, we identified a nonsense mutation (c.520C>T, exon 4) of the LAMP2 gene in a family with Danon disease. We generated iPSC lines from somatic cells derived from the affected mother and her 2 sons, and we then differentiated them into cardiomyocytes (iPSC-CMs) for modeling the histological and functional signatures, including autophagy failure of Danon disease. RESULTS: Our iPSC-CM platform provides evidence that random inactivation of the wild-type and mutant LAMP2 alleles on the X chromosome is responsible for the unusual phenotype in female patients with Danon disease. In vitro, iPSC-CMs from these patients reproduced the histological features and autophagy failure of Danon disease. Administration of the DNA demethylating agent 5-aza-2'-deoxycytidine reactivated the silent LAMP2 allele in iPSCs and iPSC-CMs in female patients with Danon disease and ameliorated their autophagy failure, supporting the application of a patient-specific iPSC platform for disease modeling and drug screening. CONCLUSIONS: Our iPSC-CM platform provides novel mechanistic and therapeutic insights into the contribution of random X chromosome inactivation to disease phenotype in X-linked Danon disease.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Ng KM, Mok PY, Butler AW, et al. Amelioration of X-Linked Related Autophagy Failure in Danon Disease With DNA Methylation Inhibitor. Circulation. 2016. PMID: 27678261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。